Blog

In May 2026, a shipment containing three months’ worth of treatment for a young girl with a rare disease, the only patient affected by this condition on the island of Mayotte, was transported from mainland France in an EMBALL’ISO VYPE insulated shipper. The shipment was worth several hundred thousand euros. Throughout 73 hours in transit (3 days), the internal temperature remained stable at around 5°C, well within the required 2–8°C range. The treatment was delivered with the cold chain intact.

In February 2025, Cyclone Garance led to the cancellation of several flights between mainland France and Réunion Island. A pallet of temperature-sensitive products, packed in EMBALL’ISO ISOGO 8L insulated packaging, was held in a cold room at the departure airport for more than 8 days. The total transit time reached 336 hours (14 days). Temperature data loggers showed that the internal temperature remained within the 2–8°C range throughout the entire journey, even as the external temperature reached up to 29°C. The shipment was successfully delivered.

In the pharmaceutical industry, securing temperature-sensitive products involves much more than selecting a passive insulated container. While the container itself is essential, the true value lies in a comprehensive ecosystem of technical services, regulatory compliance expertise, and advanced engineering. For over 35 years, EMBALL’ISO has supported pharmaceutical laboratories and healthcare logistics providers by operating a global reusable thermal protection system tailored for complex supply chains.

In brief: reusable passive insulated packaging keeps a pharmaceutical product at temperature without electricity, thanks to phase change materials (PCM) and high-performance insulation. It is more reliable, cheaper and lower in CO₂ emissions than an active container, provided it is lightweight, reused many times and can be repositioned.

Packaging choice can change the carbon footprint of a temperature-controlled pharmaceutical shipment by up to 2.8 times, according to a KEDGE Business School study led by Professor Yann Bouchery. Transportation of the loaded shipment dominates emissions, so lightweight design, real-world reusability and maritime repositioning are the three characteristics of the lowest-emission packaging.

EMBALL’ISO’s Dynamic Approach matches the level of thermal protection to each shipment (size, destination, duration, season and transport mode) instead of imposing a one-size-fits-all solution. Four levels are available: PROTECTIVE, STANDARD, PREMIUM and PREMIUM+.

The most sustainable packaging is the one that performs, returns and performs again.
For pharmaceutical supply chains, thermal packaging is no longer simply a box designed to protect a shipment.
It is a complete system.
At EMBALL’ISO, we do not simply supply packaging. We operate a global reusable thermal packaging system for pharmaceutical supply chains.

The Packaging and Packaging Waste Regulation (PPWR), Regulation (EU) 2025/40, introduces a harmonised European framework for packaging and packaging waste. It applies from 12 August 2026, with additional requirements coming into force progressively over the next few years.

For pharmaceutical and life-sciences supply chains, the PPWR increases the importance of packaging optimisation, recyclability, reuse, material information and technical documentation. For temperature-sensitive healthcare products, these requirements must be considered alongside the essential thermal and mechanical performance of the packaging.

Deep Freeze VYPE is EMBALL’ISO’s PREMIUM+ reusable insulated packaging solution, designed for shipping packages at very low temperatures (< –70°C), with a temperature hold time of up to 244 hours (more than 10 days) without re-icing. This extended autonomy significantly reduces logistics costs associated with dry ice replenishment while helping secure the cold chain.